Advancements in pharmacological, surgical and adjunct therapeutic modalities for inflammatory bowel disease

Advancements in experimental platforms have enhanced our understanding of disease-pertinent pathophysiology for inflammatory bowel diseases (IBD). This has fueled identification of novel molecular targets, thus revolutionizing treatment aspirations from symptomatic control to well-defined objective aspirations by implementation of the treat-to-target approach. Despite these rapid advances, a significant subset of patients fail to respond to therapy. This Article Collection highlights cutting edge clinical research to optimize therapeutic and alternative adjunct modalities to improve clinical outcomes and quality of life for IBD patients.